LGVN — Longeveron Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1721484 ·
Last close
$0.70
Market Cap
$21.16M
52W High
$0.90
52W Low
$0.57
ADV30
272,650
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 398,000 | 264,000 | -4,775,000 | -4,736,000 | 21,210,000 | 15,758,000 | 5,183,000 |
| Dec 2025 | 365,000 | 257,000 | -5,399,000 | -5,444,000 | 10,261,000 | 4,661,000 | 4,586,000 |
| Sep 2025 | 137,000 | 125,000 | -7,310,000 | -7,221,000 | 15,557,000 | 9,244,000 | 5,591,000 |
| Jun 2025 | 316,000 | 146,000 | -5,397,000 | -5,028,000 | 16,749,000 | 10,334,000 | 4,093,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,318,000
Investing CF
$-465,000
Financing CF
$20,214,000
CapEx
$-465,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-137,047,000
Inventory
—
Receivables
$68,000
ST Investments
$0
EBIT TTM
$-22,881,000
Pretax Income TTM
$-22,429,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,216,000
EBITDA
$-21,624,000
Free Cash Flow
$-10,452,625
Enterprise Value
$6,839,155
Total Cash
$15,758,000
Total Debt
$748,000
Shares Out
30,148,947
Trailing EPS
$-1.14
Book Value
$0.52
ROE
-135.2%
ROA
-67.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,199,000 | -23,287,000 | -22,704,000 | 10,261,000 | 4,586,000 | — | -18,645,000 |
| Dec 2024 | 2,392,000 | -16,522,000 | -15,973,000 | 25,558,000 | 3,671,000 | — | -13,868,000 |
| Dec 2023 | 709,000 | -21,029,000 | -21,413,000 | 12,078,000 | 5,337,000 | — | -19,002,000 |
| Dec 2022 | 1,222,000 | -18,043,000 | -18,835,000 | 27,413,000 | 6,910,000 | — | -13,969,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NEUP | Neuphoria Therapeutics Inc. | $20.97M | $3.88 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $20.65M | $2.07 | — |
| CLRB | Cellectar Biosciences, Inc. | $20.54M | $2.57 | — |
| SKYE | Skye Bioscience, Inc. | $20.00M | $0.57 | — |
| TVRD | Tvardi Therapeutics, Inc. | $19.70M | $2.10 | — |
News headlines (Yahoo Finance, 1h cache)
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
2026-07-23 13:15 · Yahoo
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Pat
2026-07-13 11:05 · Yahoo
Longeveron® Appoints Marie Washburn as Chief Financial Officer
2026-07-06 20:05 · Yahoo
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
2026-06-18 13:20 · Yahoo
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
2026-06-09 13:20 · Yahoo
Longeveron to Present at BIO International Convention 2026
2026-06-04 13:15 · Yahoo
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
2026-05-20 20:05 · Yahoo
Longeveron Inc. Q1 2026 Earnings Call Summary
2026-05-14 12:30 · Yahoo
LGVN Set for Success in 2026
2026-05-14 11:24 · Yahoo
Longeveron (LGVN) Q1 2026 Earnings Transcript
2026-05-13 22:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.